- Home
- STX vs ABBV Comparison
STX vs ABBV Comparison
Compare STX & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STX | ABBV |
|---|---|---|
| Founded | 1978 | 2012 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2B | 358.5B |
| IPO Year | 2002 | 2012 |
Fundamental Metrics
Financial Performance| Metric | STX | ABBV |
|---|---|---|
| Price | $869.32 | $225.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 18 |
| Target Price | ★ $604.14 | $253.71 |
| AVG Volume (30 Days) | 2.8M | ★ 3.7M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | 0.46% | ★ 3.39% |
| EPS Growth | ★ 328.48 | N/A |
| EPS | ★ 8.29 | 0.39 |
| Revenue | $7,384,000,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $27.73 | $11.87 |
| Revenue Next Year | $25.06 | $8.12 |
| P/E Ratio | ★ $98.41 | $576.97 |
| Revenue Growth | N/A | ★ 8.57 |
| 52 Week Low | $124.63 | $181.75 |
| 52 Week High | $966.80 | $244.81 |
Technical Indicators
Market Signals| Indicator | STX | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 57.81 | 64.68 |
| Support Level | $364.17 | $220.11 |
| Resistance Level | $966.80 | $231.00 |
| Average True Range (ATR) | 50.20 | 4.97 |
| MACD | -14.19 | 0.97 |
| Stochastic Oscillator | 40.69 | 83.82 |
Price Performance
Historical ComparisonAbout STX Seagate Technology Holdings PLC (Ireland)
Seagate Technology is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.